Precigen (PGEN) Non-Current Deferred Tax Liability (2015 - 2024)
Precigen (PGEN) posted quarterly Non-Current Deferred Tax Liability of $1.3 million for Q4 2024, down 88.39% year-over-year from $10.9 million in Q1 2024, and up 1328.09% quarter-over-quarter from $89000.0 in Q3 2024.
Analysis
Precigen (PGEN) Non-Current Deferred Tax Liability (2015 - 2024) Analysis & Trends
Precigen (PGEN) has reported Non-Current Deferred Tax Liability for 10 consecutive years, with $1.3 million the latest figure, recorded in Q4 2024.
- In Q4 2024, Non-Current Deferred Tax Liability fell 88.39% year-over-year to $1.3 million; the TTM figure through Dec 2024 stood at $1.3 million (down 88.39% YoY), while the FY2024 annual figure was $1.3 million, down 88.39% from the prior year.
- Non-Current Deferred Tax Liability rose to $1.3 million in Q4 2024 per PGEN's latest filing, from $89000.0 in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $18.5 million in Q4 2021 and bottomed at $77000.0 in Q2 2024.
- Historically, Non-Current Deferred Tax Liability has averaged $3.9 million across 5 years, with a median of $2.4 million in 2022.
- Annual changes were most pronounced in 2023 — Non-Current Deferred Tax Liability jumped 383.69% — and 2024, when it plunged 96.47%.
- Precigen's Non-Current Deferred Tax Liability stood at $12.6 million in 2020, then jumped by 47.0% to $18.5 million in 2021, then sank by 87.8% to $2.3 million in 2022, then surged by 383.69% to $10.9 million in 2023, then plunged by 88.39% to $1.3 million in 2024.
- Business Quant data shows PGEN's Non-Current Deferred Tax Liability at $1.3 million in Q4 2024, $89000.0 in Q3 2024, and $77000.0 in Q2 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Precigen | 2.53 Bn | 2.53 Bn | 52.17 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 1.27 Mn |
| Sep 30, 2024 | 89,000.00 |
| Jun 30, 2024 | 77,000.00 |
| Mar 31, 2024 | 1.78 Mn |
| Dec 31, 2023 | 10.95 Mn |
| Sep 30, 2023 | 2.13 Mn |
| Jun 30, 2023 | 2.18 Mn |
| Mar 31, 2023 | 2.24 Mn |
| Dec 31, 2022 | 11.44 Mn |
| Sep 30, 2022 | 2.09 Mn |
| Jun 30, 2022 | 2.26 Mn |
| Mar 31, 2022 | 2.44 Mn |
| Dec 31, 2021 | 18.54 Mn |
| Sep 30, 2021 | 2.57 Mn |
| Jun 30, 2021 | 2.69 Mn |
| Mar 31, 2021 | 2.72 Mn |
| Dec 31, 2020 | 12.62 Mn |
| Sep 30, 2020 | 2.73 Mn |
| Jun 30, 2020 | 2.70 Mn |
| Mar 31, 2020 | 2.79 Mn |